Abbott Laboratories's Revenue in the fiscal year 2025 $ 44,328.00 millions
Abbott Laboratories's Revenue in the fiscal year 2024 $ 41,950.00 millions
Abbott Laboratories's Revenue in the fiscal year 2023 $ 40,109.00 millions
Abbott Laboratories's Revenue in the fiscal year 2022 $ 43,653.00 millions
Abbott Laboratories's Revenue in the fiscal year 2021 $ 43,075.00 millions
ABT Revenue third quarter 2026 Y/Y Growth Comment
Abbott Laboratories achieved in the third quarter 2026, above Company average Revenue increase of 14.46% year on year, to $ 13,013.00 millions.
Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 96 other companies have achieved higher Revenue growth. While Abbott Laboratories' s Revenue growth of 14.46% ranks overall at the positon no. 1379 in the third quarter 2026.
Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026
Abbott Laboratories's Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
20.87 %
1.47 %
-49.08 %
(Dec 31 2020)
ABT's III. Quarter Q/Q Revenue Comment
Abbott Laboratories achieved in the III. Quarter 2026 above company average sequential Revenue growth of 3.34%, to $ 13,013.00 millions, from $12,593.00 millions in the second quarter.
Within Major Pharmaceutical Preparations industry 73 other companies have achieved higher Revenue quarter on quarter growth. While Abbott Laboratories's Revenue growth quarter on quarter, overall rank is 1346.
Abbott Laboratories achieved in the III. Quarter 2026 above company average sequential Revenue growth of 3.34%, to $ 13,013.00 millions, from $12,593.00 millions in the second quarter.
Within Major Pharmaceutical Preparations industry 73 other companies have achieved higher Revenue quarter on quarter growth. While Abbott Laboratories's Revenue growth quarter on quarter, overall rank is 1346.
Abbott Laboratories's 12 Months Revenue Growth Year on Year
Abbott Laboratories saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 10% year on year, to $ 48,229 millions if the fiscal year would have ended in Sep 30 2026. Abbott Laboratories's trailing twelve months Revenue growth was higher than company's average 5% and higher than 8.06% growth in Jun 30 2026. But from twelve months ended Jun 30 2026 rise was beneth at 3.53 % from $46585 millions achieved in the period from Jun 30 2026 to Sep 30 2025. We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at5%.
In the Healthcare sector 298 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 1922, from total ranking in previous quarter at 2269.
Abbott Laboratories saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 10% year on year, to $ 48,229 millions if the fiscal year would have ended in Sep 30 2026. Abbott Laboratories's trailing twelve months Revenue growth was higher than company's average 5% and higher than 8.06% growth in Jun 30 2026. But from twelve months ended Jun 30 2026 rise was beneth at 3.53 % from $46585 millions achieved in the period from Jun 30 2026 to Sep 30 2025. We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at5%. The momentum is even more impressive from twelve months ended Jun 30 2026 exhibited at 3.53 % increase from $46585 millions in the period from Jun 30 2026 to Sep 30 2025.
In the Healthcare sector 298 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 1922, from total ranking in previous quarter at 2269.
About Abbott Laboratories Revenue Growth Rates (ABT), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
25.30%